Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.
P/E ratio for Neuland Laboratories Limited (NEULANDLAB.NS)
P/E ratio as of 2023: 26.79
According to Neuland Laboratories Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.79. At the end of 2022 the company had a P/E ratio of 14.15.
P/E ratio history for Neuland Laboratories Limited from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 26.79 |
| 2022 | 14.15 |
| 2021 | 20.69 |
| 2020 | 33.24 |
| 2019 | 22.39 |
| 2018 | 50.37 |
| 2017 | 69.53 |
| 2016 | 50.84 |
| 2015 | 22.87 |
| 2014 | 17.83 |
| 2013 | 7.36 |
| 2012 | 5.39 |
| 2011 | 17.36 |
| 2010 | 11.94 |
| 2009 | -7.86 |
| 2008 | 4.32 |